The FDA has streamlined biosimilar approvals by eliminating the need for clinical efficacy studies (CESs) for monoclonal antibody biosimilars, relying instead on analytical and PK/PD data.
This change is expected to reduce development costs by 50-60% and shorten timelines by several years.
The move aims to increase competition, lower drug prices, and enhance patient access to biosimilars.